---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: COMPACT"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: COMPACT. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 16 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/compact"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: COMPACT

<a id="heading-3.1.9"></a>

## 3.1.9 COMPACT

<a id="heading-3.1.9.1"></a>

### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

#### Clinical objective

> “clinical efficacy of SC CSL830 in the prophylactic treatment of HAE”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.2"></a>

### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

#### Trial locations and global end date

| Field | Reported value |
| --- | --- |
| Planned region | “Argentina” |
| Planned region | “Australia” |
| Planned region | “Canada” |
| Planned region | “European Union” |
| Planned region | “United States” |
| Global end of trial | “2015-10-12” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.3"></a>

### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

#### Crossover design

> “32-week, multicenter, randomized, double-blind, placebo-controlled, crossover study”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.9.4"></a>

### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

#### Age eligibility

> “12 years or older”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.9.5"></a>

### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

#### Subcutaneous regimens and frequency

> “60 IU/kg”
> “40 IU/kg”
> “twice weekly (every 3 or 4 days)”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.9.6"></a>

### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

#### 3.1.9.6.1 Rationale for Using HAE Attack Frequency as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

##### Primary clinical endpoint

> “number of attacks of angioedema.”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.7"></a>

### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

#### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

##### Planned enrollment

| Population | Participants |
| --- | --- |
| Whole trial | “100” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="topic-3.1.9.7.1-2"></a>

##### Actual randomization

| Population | Participants |
| --- | --- |
| Randomized | “90” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.7.2"></a>

#### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

##### Efficacy evaluation window

> “Efficacy was evaluated for the last 14 weeks of each treatment period.”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.9.8"></a>

### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

#### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

##### Study completion

| Disposition | Participants |
| --- | --- |
| Completed | “79” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.8.2"></a>

#### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

##### Baseline age

| Characteristic | Reported value |
| --- | --- |
| Median age, years (range) | “40 (12 to 72)” |

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.9.8.3"></a>

#### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

##### Monthly attack-rate differences versus placebo

| Regimen | Mean difference, attacks per month |
| --- | --- |
| 40 IU/kg twice weekly | “-2.42” |
| 60 IU/kg twice weekly | “-3.51” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.8.4"></a>

#### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.9.8.4-1"></a>

##### Post hoc HRQoL analysis: instruments and timing

> “Post hoc analysis of data from the placebo-controlled, crossover phase III COMPACT study”
> “HRQoL assessments at week 14 (last visit) included the European Quality of Life-5 Dimensions Questionnaire (EQ-5D-3L), the Hospital Anxiety and Depression Scale (HADS), the Work Productivity and Activity Impairment Questionnaire (WPAI), and the Treatment Satisfaction Questionnaire for Medication (TSQM).”

Source: [Lumry et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29391286/)

<a id="topic-3.1.9.8.4-2"></a>

##### HRQoL during subcutaneous C1-INH compared with placebo

> “Compared with placebo (on-demand treatment alone), treatment with twice weekly C1-INH(SC) (both doses combined) was associated with better EQ-5D visual analog scale general health, less HADS anxiety, less WPAI presenteeism, work productivity loss, and activity impairment, and greater TSQM effectiveness and overall treatment satisfaction.”
> “For each HRQoL measure, a greater proportion of patients had a clinically meaningful improvement during C1-INH(SC) treatment compared with placebo.”

Source: [Lumry et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29391286/)

<a id="heading-3.1.9.8.5"></a>

#### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

##### Most common adverse events

> “mild and transient local site reactions”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.9.9"></a>

### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

#### Summary

The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/); [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf); [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy); [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
